NEWS
Redwire to Test 3D Bioprinted Liver Tissue in Space, Reinforcing the Company’s Focus on Transforming the Future of Organ Transplantation on Earth
Redwire (NYSE: RDW) is launching a groundbreaking experiment to the International Space Station (ISS) to analyze the effects of microgravity on tissue bioprinting and culturing. In collaboration with Wake Forest Institute of Regenerative Medicine, Redwire will culture 36 bioprinted vascularized liver tissue constructs in space. This initiative aims to determine if liver cells bioprinted on Earth can form functioning blood vessels in microgravity, potentially addressing the global organ shortage.
Redwire has made significant progress in space biotech, successfully bioprinting human knee meniscus and heart tissue samples in space. The company is also launching four drug manufacturing experiments in its PIL-BOX system, marking its third spaceflight mission in 10 months. These experiments will launch to the ISS aboard the Northrop Grumman NG-21 cargo resupply mission in early August 2024.
Redwire has made significant progress in space biotech, successfully bioprinting human knee meniscus and heart tissue samples in space. The company is also launching four drug manufacturing experiments in its PIL-BOX system, marking its third spaceflight mission in 10 months. These experiments will launch to the ISS aboard the Northrop Grumman NG-21 cargo resupply mission in early August 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1113Followers
70Following
7736Visitors
Follow